RXC006 (Porcupine inhibitor, Fibrosis)

Licensed to AstraZeneca, August 2020

Target/ Product

Indication(s)

Research

Preclinical Development

Clinical Phase 1/2

Expected Milestones

Porcupine Inhibitor
(RXC006)

Lung fibrosis (IPF)

Licensed to AstraZeneca

Redx sign licensing deal with AstraZeneca

In August 2020, Redx Pharma signed a significant out licensing agreement for our porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Under the terms of the exclusive global agreement, AstraZeneca will pay Redx several early milestones that amount to $17 million, by the time of successful commencement of a phase 1 study. In addition, Redx is eligible to receive up to a further $360 million from AstraZeneca in development, regulatory and commercial milestone payments throughout the course of the programme should it successfully reach these milestones. Redx is also eligible for tiered royalties of mid-single digit percentages, based on any future net sales.

Read the press release

Fibrotic diseases such as idiopathic pulmonary fibrosis have significant impact on patients’ lives and new therapies are urgently needed. We look forward to progressing this porcupine inhibitor into clinical trials as a novel approach to supress Wnt signalling and potentially modify fibrotic disease processes.

Mene Pangalos

Executive Vice President BioPharmaceuticals R&D, AstraZeneca

About RXC006

Porcupine is a novel drug target that aims to address the issue of high unmet need in fibrosis and is a key enzyme in the Wnt signalling pathway. Aberrant Wnt signalling is involved in fibrogenesis, and inhibition of Wnt signalling is likely to prevent several mechanisms important for fibrotic disease progression. Current treatments for fibrosis provide limited benefit and there is an urgent need to develop new therapies to treat fibrotic conditions. Recent publications have shown that Porcupine inhibitors are effective in preclinical models and could be beneficial in the treatment of fibrotic indications, including renal, heart, lung and skin conditions.

RXC006 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Our scientists have demonstrated that RXC006 potently inhibits porcupine resulting in striking anti-fibrotic effects in animal models of kidney, liver and lung fibrosis. RXC006 was nominated as a candidate for development in Idiopathic Pulmonary Fibrosis. RXC006 is from a different chemical series to our lead oncology asset RXC004 and is protected by a separate composition of matter patent. Following the licensing agreement, AstraZeneca will take RXC006 forward into clinical development targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).

Porcupine inhibitor, RXC006 suppresses fibrosis in a bleomycin-induced mouse model of IPF

Image representative of group mean Ashcroft scores. Scale bar indicates 1.2 mm. Small region of dense collagenous connective tissue (fibrosis; black arrows demarcate) and lymphocyte infiltrates/aggregates (*) are present. A bronchiole (Br) and blood vessels (BV) are indicated.